Critically Ill Pediatric Patients Meropenem, Therapeutic drug monitoring, Extended infusion, Intermittent bolus, Critically ill, Pediatric
Conditions
Interventions
Critically ill pediatric patients who have pathophysiological changes that occur during sepsis and effects on pharmacokinetics (volume of distribution and clearance) that affect to drug level in plasm
Other
Critically ill pediatric patients
Sponsors
Clinical pharmacokinetics and pharmacogenomics research unit
Eligibility
Sex/Gender
All
Age
1 Months to 18 Years
Inclusion criteria
Inclusion criteria: 1. Pediatric patients ranged in age from 1 month to 18 years who admit into pediatric wards in King Chulalongkorn Memorial Hospital 2. Patients were received meropenem 3. Body weight more than 3 kilograms 4. CVC or A-line
Exclusion criteria
Exclusion criteria: 1. Patients were received valproic acid, probenecid, Patients were received valproic acid and probenecid 2. GFR is less than 60 ml/min/1.73 m2 3. Use or plan of ECMO and RRT 4. Penicillin allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic drug monitoring of meropenem 4 and 8 h Meropenem level in plasma | — |
Secondary
| Measure | Time frame |
|---|---|
| Therapeutic drug monitoring of meropenem 4 and 8 h clinical outcome | — |
Countries
Thailand
Contacts
Public ContactPassara Maimongkol
Faculty of medicine, Chulalongkorn University
Outcome results
None listed